Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of GF-CART01, a CD20/CD19 CAR T cell therapy, evaluating safety and early activity in adults with relapsed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• GF-CART01

Snippet

Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. | Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1 | Status: RECRUITING